Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ARG1 | P05089 | 5/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220789 | 1.00 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL29053592 | 1.00 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL220788 | 1.00 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL12283182 | 1.00 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| Hydrochloric Acid SCHEMBL5955670 | 0.98 | MEN1 (0.59) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL312743 | 0.86 | — | — | |
| SCHEMBL4588183 | 0.86 | — | — | |
| SCHEMBL312745 | 0.86 | — | — | |
| SCHEMBL5207176 | 0.86 | — | — | |
| SCHEMBL6079315 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-8809330-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2585467-A1 | PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | MEN1 3424/4885BLM 4803/4885KMT2A 2031/4885 |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | MEN1 885/4885BLM 4818/4885KMT2A 809/4885 |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MEN1 3578/4885BLM 1885/4885KMT2A 3648/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | MEN1 3424/4885BLM 4803/4885KMT2A 2031/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MEN1 3578/4885BLM 1885/4885KMT2A 3648/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | MEN1 3424/4885BLM 4803/4885KMT2A 2031/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MEN1 3578/4885BLM 1885/4885KMT2A 3648/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | MEN1 3424/4885BLM 4803/4885KMT2A 2031/4885 |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | MEN1 885/4885BLM 4818/4885KMT2A 809/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | MEN1 3424/4885BLM 4803/4885KMT2A 2031/4885 |
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | MEN1 3397/4885BLM 1602/4885KMT2A 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.